GRCE — Grace Therapeutics, Cashflow Statement
0.000.00%
Last trade - 00:00- $44.94m
- $24.94m
- 21
- 55
- 74
- 48
Annual cashflow statement for Grace Therapeutics,, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -19.7 | -9.82 | -42.4 | -12.9 | -9.57 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 10.4 | -4.63 | 26.2 | 1.79 | -5.68 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.95 | -2.79 | 0.181 | -1.28 | 0.342 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -14.3 | -17.2 | -15.9 | -12.3 | -14.9 |
| Capital Expenditures | -0.069 | 0 | -0.017 | -0.022 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -9.79 | -3.52 | 13.2 | 0.126 | 0 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.86 | -3.52 | 13.2 | 0.104 | 0 |
| Financing Cash Flow Items | -0.143 | 0 | — | — | -0.967 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 59.5 | 0 | 0.304 | 7.36 | 14 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 36.7 | -20.6 | -2.46 | -4.87 | -0.872 |